MARKET

HUMA

HUMA

Humacyte Inc
NASDAQ
0.5828
-0.0072
-1.22%
Pre Market: 0.5879 +0.0051 +0.88% 08:28 09/23 EDT
OPEN
0.5876
PREV CLOSE
0.5900
HIGH
0.6079
LOW
0.5811
VOLUME
31.42K
TURNOVER
0
52 WEEK HIGH
2.550
52 WEEK LOW
0.5261
MARKET CAP
161.90M
P/E (TTM)
-1.1906
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)
TipRanks · 1d ago
Weekly Report: what happened at HUMA last week (0914-0918)?
Weekly Report · 2d ago
Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know
NASDAQ · 4d ago
Weekly Report: what happened at HUMA last week (0907-0911)?
Weekly Report · 09/14 10:11
Humacyte's Symvess Shelf Life Extended To 36 Months Following FDA Authorization
NASDAQ · 09/09 14:52
Humacyte announces FDA extension of expiration dating period for Symvess
TipRanks · 09/09 12:21
Humacyte Receives FDA Authorization To Extend The Expiration Dating Period For Symvess From 18 To 36 Months
Benzinga · 09/09 12:06
Weekly Report: what happened at HUMA last week (0831-0904)?
Weekly Report · 09/07 10:05
More
About HUMA
Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

Webull offers Humacyte Inc stock information, including NASDAQ: HUMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HUMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading HUMA stock methods without spending real money on the virtual paper trading platform.